Literature DB >> 31023615

A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.

Federico Piñero1, Martín Vazquez2, Patricia Baré3, Cristian Rohr2, Manuel Mendizabal4, Mariela Sciara2, Cristina Alonso4, Fabián Fay2, Marcelo Silva4.   

Abstract

INTRODUCTION AND AIM: A pro-oncogenic intestinal microbiome was observed in murine models; however, no specific microbiome in patients with hepatocellular carcinoma (HCC) has been reported. We aimed to compare the gut microbiome found in cirrhotic patients with or without HCC.
MATERIALS AND METHODS: From 407 patients with Child Pugh A/B cirrhosis prospectively followed, 25 with HCC (cases) were matched with 25 without HCC (wo-HCC) in a 1:1 ratio according to age, gender, etiology, Child Pugh and severity of portal hypertension. In addition, results were also compared with 25 healthy subjects. Fecal stool samples were sequenced for the V3-V4 region of the microbial 16S rRNA (Illumina MiSeq Platform). Plasma cytokines were quantified including interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α).
RESULTS: We found a differential abundance in family members of Firmicutes with a 3-fold increase of Erysipelotrichaceae and a 5-fold decrease in family Leuconostocaceae in HCC when compared to wo-HCC controls. Genus Fusobacterium was found to be 5-fold decreased in HCC vs wo-HCC. The ratio bacteriodes/prevotella was increased in HCC. Three operational taxonomic units (OTUs), genus Odoribacter and Butyricimonas were more abundant in HCC, whereas a decreased abundance in Lachnospiraceae family genus Dorea was observed in HCC patients. A Random Forest model trained with differential abundant taxa correctly classified HCC individuals. This pattern was associated with an inflammatory milieu with a putative increased activation of NOD-like receptor pathways.
CONCLUSION: We found a pattern of microbiome linked to inflammation that could be potentially useful as HCC biomarker after follow-up validation studies.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Inflammatory pathways; Liver cancer; Microbiota

Mesh:

Substances:

Year:  2019        PMID: 31023615     DOI: 10.1016/j.aohep.2018.10.003

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  12 in total

1.  Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.

Authors:  Farzam Vaziri; Steven Colquhoun; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-10-17

Review 2.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

Review 3.  Trust Your Gut: The Association of Gut Microbiota and Liver Disease.

Authors:  Ridda Manzoor; Weshah Ahmed; Nariman Afify; Mashal Memon; Maryam Yasin; Hamda Memon; Mohammad Rustom; Mohannad Al Akeel; Noora Alhajri
Journal:  Microorganisms       Date:  2022-05-18

Review 4.  Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment.

Authors:  Federico Piñero; Melisa Dirchwolf; Mário G Pessôa
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

5.  Bifidobacterium longum R0175 Protects Rats against d-Galactosamine-Induced Acute Liver Failure.

Authors:  Kaicen Wang; Longxian Lv; Ren Yan; Qiangqiang Wang; Huiyong Jiang; Wenrui Wu; Yating Li; Jianzhong Ye; Jingjing Wu; Liya Yang; Xiaoyuan Bian; Xianwan Jiang; Yanmeng Lu; Jiaojiao Xie; Qing Wang; Jian Shen; Lanjuan Li
Journal:  mSphere       Date:  2020-01-29       Impact factor: 4.389

6.  Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis.

Authors:  Zhiyu Yang; Qiaoyun Xia; Di Lu; Han Yue; Jianmin Zhang; Yalong Li; Bingyong Zhang; Xiuling Li; Mingbo Cao
Journal:  Aging (Albany NY)       Date:  2020-11-08       Impact factor: 5.682

7.  Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study.

Authors:  Andreas Blesl; Christoph Jüngst; Frank Lammert; Günter Fauler; Florian Rainer; Bettina Leber; Nicole Feldbacher; Silvia Stromberger; Renate Wildburger; Walter Spindelböck; Peter Fickert; Angela Horvath; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2020-09-07       Impact factor: 5.717

Review 8.  Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.

Authors:  Valentina Liakina; Sandra Strainiene; Ieva Stundiene; Vaidota Maksimaityte; Edita Kazenaite
Journal:  World J Hepatol       Date:  2022-07-27

Review 9.  The Endless Sources of Hepatocellular Carcinoma Heterogeneity.

Authors:  Marina Barcena-Varela; Amaia Lujambio
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 10.  Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management.

Authors:  Jinghang Xu; Qiao Zhan; Yanan Fan; Emily Kwun Kwan Lo; Fangfei Zhang; Yanyan Yu; Hani El-Nezami; Zheng Zeng
Journal:  Pathogens       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.